Rod-Shaped Nanoparticles Cloaked in Stem Cell Membranes Cross the Blood-Brain Barrier to Fight Glioma

Glioma remains one of the most formidable enemies in modern oncology. It is the most common and aggressive primary malignancy of the central nervous system, accounting for roughly 80 percent of all malignant brain tumors, and even with surgery, radiotherapy, and temozolomide-based chemotherapy, patients with high-grade disease typically survive fewer than 15 months, with recurrence nearly universal. A central reason for this grim outlook is the blood-brain barrier, the highly selective vascular interface that shields the brain from most circulating molecules. Active efflux transporters at the barrier pump chemotherapeutics back into the bloodstream, and the blood-tumor barrier compounds the problem further, leaving drug concentrations at the tumor site insufficient for sustained cytotoxicity. For decades, researchers have sought delivery vehicles capable of slipping past this biological checkpoint, and a new study published in Materials Today Bio now suggests that one of the most overlooked design variables in nanomedicine, the sheer shape of the particle itself, may hold a decisive key.

A team of researchers led by Yue Gong and Wei Lv engineered a family of biomimetic nanocarriers in which mesoporous silica nanoparticles were coated with membranes harvested from mesenchymal stem cells and loaded with the chemotherapy drug doxorubicin. Mesenchymal stem cells were chosen as the membrane source for good reason: these cells naturally exhibit tropism toward injured and tumor-associated tissues and can migrate across the blood-brain barrier toward glioma lesions. By wrapping the synthetic silica cores in stem cell membranes, the researchers hoped to transfer membrane-associated features involved in endothelial interaction, immune tolerance, and tumor homing onto the drug carriers. Crucially, unlike whole-cell therapies, the biological functions of these membrane-coated nanoparticles arise from retained surface proteins rather than paracrine secretion, offering a controllable and drug-loaded platform.

The truly novel element of the study, however, was its systematic interrogation of particle morphology. While the overwhelming majority of brain-targeted nanodelivery research has focused on optimizing particle size, surface charge, ligand density, and pore architecture, the influence of shape has remained poorly characterized. Using a template-based synthesis in which increasing concentrations of the surfactant CTAB drove the formation of progressively elongated particles, the team produced three distinct geometries: spheres with an aspect ratio of approximately 1, short rods with an aspect ratio of about 1.5, and long rods with an aspect ratio near 3. Transmission electron microscopy confirmed uniform, well-defined particles with highly ordered porous channels, and dynamic light scattering showed hydrodynamic diameters of 188.3, 192.4, and 254.1 nanometers respectively, all with low polydispersity indices and negative zeta potentials that favored subsequent membrane coating.

To ensure that any biological differences could be attributed to shape rather than to confounding formulation variables, the researchers carefully standardized everything else. Doxorubicin was loaded by electrostatic adsorption at a drug-to-particle ratio of 1:1, yielding a loading level of approximately 43 percent across all three morphologies. After coating, western blot analysis confirmed that key mesenchymal stem cell membrane proteins, including CD47, CXCR4, and VLA-4, were preserved on the surface of all coated particles, with the membrane reference protein ATP1A1 showing comparable signals across formulations. In vitro release profiles were similarly indistinguishable, with cumulative doxorubicin release reaching approximately 26 percent within 12 hours and no burst release, and the particles remained stable in storage for over a week. The stage was thus set for a clean comparison of geometry alone.

The first hint of a shape effect emerged from multiple-particle tracking, a sensitive optical technique that captures the motion trajectories of individual nanoparticles in fluid. Spherical particles moved within a relatively limited area, whereas both short-rod and long-rod particles displayed a broader movement range. Quantitative analysis revealed that rod-shaped particles exhibited higher mean square displacement, average velocity, and diffusion coefficient than their spherical counterparts, with the long rods showing the greatest motility of all. The researchers attribute this enhanced motility to translational-rotational coupling and hydrodynamic effects associated with shape anisotropy. In practical terms, faster-diffusing particles have a higher probability of making contact with target cells after being transported through the bloodstream, which sets the stage for more efficient cellular interaction and transmembrane transport.

Those predictions held up in cell-based experiments. In both bEnd.3 brain endothelial cells and GL261 glioma cells, fluorescence signals intensified with increasing aspect ratio, and the long rod-shaped particles were taken up significantly more than the other two groups. Importantly, uncoated silica particles showed the same morphology-dependent uptake pattern, demonstrating that particle geometry itself makes an important contribution to cellular internalization rather than the effect being purely a product of the membrane coating. In a Transwell model of the blood-brain barrier, in which endothelial cells formed a tight barrier confirmed by transepithelial electrical resistance measurements above 200 ohms per square centimeter, all three formulations crossed to some degree, but the long rods achieved the highest transport efficiency at every time point tested. In three-dimensional GL261 tumor spheroids, the contrast was even more striking: spherical particle fluorescence was largely confined to the outer shell of the spheroid, fading beyond 40 micrometers of depth, while long-rod fluorescence remained strong even in the deepest scanned layers.

To understand the mechanism, the researchers turned to bio-transmission electron microscopy and surface plasmon resonance. The electron micrographs revealed that spherical particles typically made localized membrane contact and were internalized through small flask-shaped invaginations enclosing single particles, whereas rod-shaped particles formed extended contact along the cell membrane with more pronounced membrane wrapping and invagination structures. Surface plasmon resonance measurements quantified these differences: long rods showed the highest association rate constant and the lowest dissociation rate constant, yielding the lowest equilibrium dissociation constant and therefore the fastest, most stable binding to the endothelial cell surface. Spherical particles, by contrast, bound weakly, with an equilibrium dissociation constant of 1.07 times ten to the minus four molar. Endocytosis inhibitor experiments added another layer of insight. Uptake of all formulations was energy-dependent, dropping sharply at 4 degrees Celsius, but spherical particles were internalized mainly through lipid raft and caveolae-related pathways, while rods increasingly engaged clathrin-mediated endocytosis as their aspect ratio grew, suggesting that stronger initial binding drives more complex and efficient entry routes.

The decisive test came in living animals. In mice bearing intracranial GL261 gliomas, fluorescently labeled long-rod particles produced the strongest cerebral fluorescence signal throughout a 24-hour observation window, and ex vivo analysis of isolated brains confirmed the highest brain-associated fluorescence in this group, reaching 4.014 times ten to the seventh in quantitative region-of-interest analysis. The retained CD47 on the membrane coating likely helped the particles evade rapid immune clearance, prolonging circulation and supporting accumulation. In the therapeutic study, mice received five intravenous doses of each formulation, and bioluminescence imaging tracked tumor growth over four weeks. Tumors in the long-rod treatment group showed a 46.61 percent decrease in bioluminescence intensity on day 28 compared with day 14, and histological staining confirmed the greatest induction of tumor cell apoptosis and the strongest suppression of the proliferation marker Ki67 in this group.

Survival data delivered the most clinically resonant result. Median survival times were 25.5 days for saline-treated mice, 26.5 days for free doxorubicin, and 28.5 days for both the spherical and short-rod formulations, but mice receiving the long-rod particles survived a median of 37.0 days, a benefit that remained statistically significant after rigorous correction for multiple comparisons. Two mice in the long-rod group were still alive at the end of the observation period. Safety testing in healthy mice showed stable body weight, normal liver and kidney biochemistry, and no pathological abnormalities on organ histology, indicating no obvious systemic toxicity under the tested regimen.

The authors are careful to frame their conclusions appropriately. The shape effects were evaluated using only three morphologies within a single mesoporous silica platform, and the coated and uncoated series were assessed in independent experimental sets, so the independent contribution of the membrane coating and its potential interaction with geometry remain to be quantitatively resolved. Future work incorporating atomic force microscopy, membrane mechanics measurements, and computational simulations of membrane wrapping will be needed to fully explain the biophysics at play. Even so, the message is clear and potentially transformative: in the rational design of brain-targeted drug delivery, particle shape is not a cosmetic detail but a first-order optimization parameter. For a disease where nearly every therapeutic advance is thwarted by the blood-brain barrier, the demonstration that simply stretching a nanoparticle into a rod can dramatically improve its journey from bloodstream to brain tumor offers an elegant, manufacturable, and deeply counterintuitive new lever for the fight against glioma.

Subject of Research: Shape-dependent transmembrane transport of mesenchymal stem cell membrane-coated mesoporous silica nanoparticles for enhanced anti-glioma drug delivery across the blood-brain barrier

Article Title: Shape-dependent transmembrane transport of mesenchymal stem cell membrane-coated mesoporous silica nanoparticles enhances anti-glioma therapy

Article References: Shape-dependent transmembrane transport of mesenchymal stem cell membrane-coated mesoporous silica nanoparticles enhances anti-glioma therapy. (n.d.). https://doi.org/10.1016/j.mtbio.2026.103703

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103703

Keywords: glioma, blood-brain barrier, mesenchymal stem cell membrane, mesoporous silica nanoparticles, particle shape, doxorubicin, biomimetic nanocarriers, drug delivery, endocytosis, surface plasmon resonance, nanomedicine, brain tumor therapy